Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Annals of the Rheumatic Diseases

Volumn 66, Issue 9, 2007, Pages 1162-1167

  Nishimoto, Norihiro ^a   Hashimoto, Jun ^a   Miyasaka, Nobuyuki ^b   Yamamoto, Kazuhiko ^c   Kawai, Shinichi ^d   Takeuchi, Tsutomu ^e   Murata, Norikazu ^f   Van Heijde, Desiree Der ^g   Kishimoto, Tadamitsu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^e Department of Gastroenterology   (Japan)

^f Kyowakai Hospital   (Japan)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; BUCILLAMINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FENOFIBRATE; INTERLEUKIN 6; METHOTREXATE; MIZORIBINE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CELLULITIS; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOOT DISEASE; FOOT RADIOGRAPHY; GASTROENTERITIS; HAND DISEASE; HAND RADIOGRAPHY; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; INJECTION SITE ERYTHEMA; LIPID METABOLISM; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PERIANAL ABSCESS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; X RAY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; INTERLEUKIN-6; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447300492     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.068064     Document Type: Article

References (35)

1. Harris ED Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006;18:277-81.
3. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9.
4. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8.
5. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. lnterleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Mineral Res 1996;11:88-95.
6. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-801.
7. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. lnterleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
8. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989;83:585-92.
9. Miyasaka N, Sato K, Hashimoto J, Kohsaka H, Yamamoto K, Goto M, et al. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. Clin Immunol Immunopathol 1989;52:238-47.
10. Bhardwaj N, Santhanam U, Lau LL, Tatter SB, Ghrayeb J, Rivelis M, et al. IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. J Immunol 1989;143:2153-9.
11. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-5.
12. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4.
13. Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45-51.
14. Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martin-Mola E, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069-75.
15. Roux-Lombard P, Eberhardt K, Saxne T, Dover JM, Wollheim FA. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology 2001;40:544-51.
16. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.
17. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-93.
18. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993;53:851-6.
19. Choy EHS, Isenberg DA, Garrood T, Farrow S, loannou Y, Bird H, et al. Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum 2002;46:3143-50.
20. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study or repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30:1426-35.
21. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
22. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
25. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002;47:215-8.
26. Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Ensyo 1996;16:437-58.
27. Ito S, Gross WL, Reinhold-Keller E, Gause A, Aries P, Ruther W, et al. Rheumatology in Japan, Germany, and Egypt: a comparison of medical practices. Acta Medica et Biologica 2006;54:51-58.
28. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
29. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
30. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
31. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
32. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of Anti-TNF-α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis. Ann N Y Acad Sci 2006;1069:414-9.
33. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
34. Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006;98:14-8.
35. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003;21:1787-803.